Whalesbook
🟢 SCENARIO A: For Earnings, Buybacks, or Financial Updates
📉 The Financial Deep Dive
The Numbers:
- Q3 FY26: Revenue stood at ₹3,567 Cr, a strong 11.5% increase year-on-year (YoY). Domestic revenue grew 11.1% YoY to ₹3,046 Cr, and Exports revenue increased 14.1% YoY to ₹521 Cr. Adjusted EBITDA margin was reported at 25.9%, down 170 bps YoY. Profit After Tax (PAT) saw a 9.5% YoY increase to ₹414 Cr, with a PAT margin of 11.6% (down 20 bps YoY). Diluted Earnings Per Share (EPS) for the quarter was ₹9.9, up 6.7% YoY.
- 9M FY26: Revenue from Operations grew 18.7% YoY to ₹10,835 Cr. Domestic revenue increased 14.8% YoY to ₹9,331 Cr, and Exports revenue surged 50.8% YoY to ₹1,504 Cr. Adjusted EBITDA margin was 24.9% (down 190 bps YoY). PAT declined 12.6% YoY to ₹1,379 Cr, with the PAT margin falling to 12.7% (down 460 bps YoY). Diluted EPS for the nine months stood at ₹32.9, a decrease of 15.4% YoY.
The Quality:
Revenue growth remains a strong suit for Mankind Pharma, with both domestic and export segments showing healthy increases. The substantial 50.8% YoY surge in export revenue for the nine-month period is particularly noteworthy. However, profitability metrics are under pressure. Adjusted EBITDA margins compressed by 170 bps in Q3 and 190 bps for the nine months, indicating rising costs or pricing challenges. While Q3 PAT grew by 9.5%, the nine-month PAT saw a significant decline of 12.6%, accompanied by a sharp 460 bps contraction in the PAT margin. The improvement in the Cash Flow from Operations (CFO) to Adjusted EBITDA ratio to 93% (from 80% in FY25) is a positive signal, suggesting better working capital management and cash generation efficiency, despite the reported margin dips. EBITDA adjustments for labour code regulations and non-recurring costs were noted.
The Grill:
Management expresses confidence in sustained long-term growth, citing four strategic pillars: steady base business, fast-growing specialty chronic, high-potential OTC business, and the super specialty BSV portfolio. The company anticipates growth to accelerate. Initiatives within the BSV portfolio are reportedly yielding strong double-digit growth, a positive sign for future diversification and profitability. However, specific analyst questions regarding margin sustainability or the drivers of the 9M PAT decline were not detailed in the provided text.
🚩 Risks & Outlook
The primary risk for Mankind Pharma lies in its ability to arrest the margin compression and improve profitability, especially as the company navigates cost pressures and potential pricing dynamics in key markets. The substantial decline in 9M PAT and EPS warrants investor attention. While management guidance is optimistic about future growth acceleration, the market will scrutinize the execution and the actual recovery in margins and earnings. Investors should watch the performance of the specialty chronic and BSV segments, as well as the continued success of new product launches in the US market, to gauge the company's ability to translate revenue growth into bottom-line improvement.